Limits of stop-reason data
Unknown clinical trial stop reasons are a result, not missing analysis
9,586 stopped records, or 40.6% of the current database, remain other or unknown. Preserving that uncertainty is part of reliable analysis, not unfinished classification work.
- The current database contains 9,586 other/unknown records, representing 40.6% of 23,617 stopped trials.
- 5,784 other/unknown records are terminated, 3,515 are withdrawn, and 287 are suspended.
- Oncology is the largest disease-area slice with 3,126 other/unknown records.
- Phase II is the largest phase group with 2,888 other/unknown records.
- Other/unknown means the public source does not support a more specific label; it does not prove a scientific or non-scientific cause.
The largest classification is uncertainty
A stopped clinical trial looks like a simple event until the reason field is opened. In the current database, 9,586 of 23,617 records (40.6%) remain other or unknown because the available text does not support a defensible efficacy, safety, operational, or regulatory classification.
That is not an invitation to guess or an indication that analysis is incomplete. It is a measurable result about the limits of public registry language and the confidence that can reasonably be attached to it.
Why records remain unknown
Registry explanations can be absent, generic, circular, or too short to separate scientific from non-scientific causes. A phrase such as sponsor decision or study stopped may be factually true without explaining whether efficacy, safety, enrollment, strategy, or another issue drove the decision.
The public record can also lag behind company announcements or omit details available in publications, conference presentations, regulatory documents, or investor disclosures. The compact source field should not be made more precise than the evidence allows.
Unknown does not mean harmless
An unknown classification does not prove that the stop was administrative. Some of these records may involve efficacy or safety issues that are not described clearly enough in the registry. Others may be routine operational decisions. The category contains uncertainty, not reassurance.
That is why it should remain searchable and visible. Hiding unknowns would make the classified groups look more complete than they are and could produce false confidence in disease-area, sponsor, or phase comparisons.
The status mix shows why wording matters
Other/unknown records appear across terminated, withdrawn, and suspended statuses. Status does not resolve the ambiguity. A terminated record can have an unclear reason, just as a withdrawn record can contain a specific safety or efficacy explanation.
The correct analytical sequence is status first, reason second, source verification third. Reversing that sequence encourages the common mistake of treating every terminated trial as a failed drug.
How I would investigate an unknown record
I would begin with the original ClinicalTrials.gov page and update history. Next I would search the exact NCT ID in sponsor releases, publications, regulatory material, conference abstracts, and archived program descriptions. Dates matter because a registry update may follow the underlying decision by weeks or months.
If the evidence still does not support a defensible reason, I would leave the record unknown. A transparent limitation is more useful than a confident label manufactured from weak text.
Why this improves the database
A high-quality database is not the one that assigns the most labels. It is the one that distinguishes evidence from inference and inference from absence. Preserving other/unknown protects the more specific efficacy, safety, operational, and regulatory categories from contamination.
It also identifies where better disclosure would create the most value. The unknown bucket is therefore both a limitation and a research agenda: it shows where the public evidence is not yet strong enough for the conclusion people often want to draw.
Other and unknown records by status
| Trial status | Other/unknown records |
|---|---|
| Terminated | 5,784 |
| Withdrawn | 3,515 |
| Suspended | 287 |
Largest other/unknown disease-area slices
| Disease area | Other/unknown records |
|---|---|
| Oncology | 3,126 |
| Other | 2,539 |
| Infectious Disease | 716 |
| Gastroenterology & Hepatology | 593 |
| Cardiovascular | 473 |
| Neurology | 383 |
| Endocrine & Metabolic | 338 |
| Immunology & Autoimmune | 267 |
Largest other/unknown phase groups
| Phase | Other/unknown records |
|---|---|
| Phase II | 2,888 |
| Phase I | 1,978 |
| Phase III | 1,342 |
| Phase IV | 1,113 |
| Phase I + Phase II | 949 |
| Unknown | 764 |
| Phase II + Phase III | 298 |
| Early Phase I | 254 |
Continue from here
FAQ
Why are so many clinical trial stop reasons unknown?
9,586 records (40.6%) are currently other or unknown. Many contain no explanation or language too general to separate scientific, operational, strategic, or regulatory causes confidently.
Does other or unknown mean the drug did not fail?
No. It means the available source language does not support a confident classification. The underlying reason may be scientific or non-scientific and requires additional evidence.
Should unknown records be excluded from analysis?
Usually not. Excluding them can exaggerate the apparent completeness of classified results. They should be reported transparently and separated from more specific categories.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.